2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis.
作者信息
Singh Jasvinder A, Furst Daniel E, Bharat Aseem, Curtis Jeffrey R, Kavanaugh Arthur F, Kremer Joel M, Moreland Larry W, O'Dell James, Winthrop Kevin L, Beukelman Timothy, Bridges S Louis, Chatham W Winn, Paulus Harold E, Suarez-Almazor Maria, Bombardier Claire, Dougados Maxime, Khanna Dinesh, King Charles M, Leong Amye L, Matteson Eric L, Schousboe John T, Moynihan Eileen, Kolba Karen S, Jain Archana, Volkmann Elizabeth R, Agrawal Harsh, Bae Sangmee, Mudano Amy S, Patkar Nivedita M, Saag Kenneth G
机构信息
University of Alabama at Birmingham.510 20th Street South, Birmingham, AL 35294, USA.
出版信息
Arthritis Care Res (Hoboken). 2012 May;64(5):625-39. doi: 10.1002/acr.21641.
Abstract
摘要
相似文献
1
2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis.2008年美国风湿病学会关于使用改善病情抗风湿药和生物制剂治疗类风湿关节炎的建议的2012年更新版。
Arthritis Care Res (Hoboken). 2012 May;64(5):625-39. doi: 10.1002/acr.21641.
2
The 2008 American College of Rheumatology recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis: where the rubber meets the road.2008年美国风湿病学会关于非生物和生物改善病情抗风湿药在类风湿关节炎中应用的推荐意见：实际应用情况
Arthritis Rheum. 2008 Jun 15;59(6):757-9. doi: 10.1002/art.23723.
3
Level of the indication of biologic agents in the 2012 American College of Rheumatology recommendations for the treatment of rheumatoid arthritis: comment on the article by Singh et al.2012年美国风湿病学会类风湿关节炎治疗推荐中生物制剂的适应证水平：对辛格等人文章的评论
Arthritis Care Res (Hoboken). 2013 May;65(5):832. doi: 10.1002/acr.21873.
4
Oral glucocorticoids should be included in any recommendation for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in the treatment of rheumatoid arthritis: comment on the article by Singh et al.在类风湿关节炎治疗中，关于使用非生物和生物改善病情抗风湿药物的任何建议都应包括口服糖皮质激素：对辛格等人文章的评论
Arthritis Care Res (Hoboken). 2012 Oct;64(10):1622-3; author reply 1623-4. doi: 10.1002/acr.21809.
5
American College of Rheumatology treatment guidelines continue to omit guidance on glucocorticoids: comment on the article by Singh et al.美国风湿病学会治疗指南仍未包含关于糖皮质激素的指导意见：对辛格等人文章的评论
Arthritis Care Res (Hoboken). 2012 Oct;64(10):1622. doi: 10.1002/acr.21770.
6
American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis.美国风湿病学会2008年关于类风湿关节炎中使用非生物和生物改善病情抗风湿药物的建议。
Arthritis Rheum. 2008 Jun 15;59(6):762-84. doi: 10.1002/art.23721.
7
Updated recommendations for the treatment of rheumatoid arthritis: another step on a long road.类风湿关节炎治疗的更新建议：漫长道路上的又一步。
Arthritis Care Res (Hoboken). 2012 May;64(5):648-51. doi: 10.1002/acr.21659.
8
Reply: To PMID 22473917.回复：致PMID 22473917。
Arthritis Care Res (Hoboken). 2013 May;65(5):832-3. doi: 10.1002/acr.21872.
9
2017 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty.2017 年美国风湿病学会/美国髋膝关节外科医师学会择期全髋关节或全膝关节置换术患者风湿性疾病抗风湿药物围手术期管理指南。
Arthritis Rheumatol. 2017 Aug;69(8):1538-1551. doi: 10.1002/art.40149. Epub 2017 Jun 16.
10
Current therapeutic agents and treatment paradigms for the management of rheumatoid arthritis.类风湿关节炎治疗的现有治疗药物和治疗模式。
Am J Manag Care. 2014 May;20(7 Suppl):S136-44.
引用本文的文献
1
A Review of the Current Clinical Aspects of Sjögren's Disease: Geographical Difference, Classification/Diagnostic Criteria, Recent Advancements in Diagnostic Methods, and Molecular Targeted Therapy.干燥综合征当前临床状况综述：地域差异、分类/诊断标准、诊断方法的最新进展以及分子靶向治疗
J Clin Med. 2025 Aug 7;14(15):5577. doi: 10.3390/jcm14155577.
2
Pharmacogenomics of TNF inhibitors.肿瘤坏死因子抑制剂的药物基因组学
Front Immunol. 2025 May 21;16:1521794. doi: 10.3389/fimmu.2025.1521794. eCollection 2025.
3
Cancer recurrence risk with bDMARD treatment in patients with rheumatoid arthritis and a history of cancer: a nationwide Danish register-based cohort study.类风湿关节炎合并癌症病史患者使用生物改善病情抗风湿药（bDMARD）治疗后的癌症复发风险：一项基于丹麦全国登记的队列研究。
RMD Open. 2025 Apr 20;11(2):e005247. doi: 10.1136/rmdopen-2024-005247.
4
Interindividual variability and its impact on the effectiveness of Janus kinase inhibitors in rheumatoid arthritis treatment.个体间变异性及其对类风湿关节炎治疗中Janus激酶抑制剂疗效的影响。
Front Med (Lausanne). 2025 Mar 28;12:1512501. doi: 10.3389/fmed.2025.1512501. eCollection 2025.
5
Management of IgG4-related cholangitis: diagnosis, therapy, and long-term surveillance.IgG4相关性胆管炎的管理：诊断、治疗及长期监测
Gastroenterol Rep (Oxf). 2025 Apr 4;13:goaf032. doi: 10.1093/gastro/goaf032. eCollection 2025.
6
Detection of substantial numbers of latent tuberculosis and positive hepatitis B serology results in rheumatology patients preparing to receive intensified immunosuppressive therapy in a low-prevalence country: why screening still matters.在一个低流行率国家，对准备接受强化免疫抑制治疗的风湿病患者进行大量潜伏性结核检测及乙肝血清学结果呈阳性：筛查为何仍然重要。
Clin Rheumatol. 2025 Apr;44(4):1851-1859. doi: 10.1007/s10067-025-07350-x. Epub 2025 Feb 25.
7
The pattern of anti-IL-6 versus non-anti-IL-6 biologic disease modifying anti-rheumatic drugs use in patients with rheumatoid arthritis in Wales, UK: a real-world study using electronic health records.英国威尔士类风湿关节炎患者中抗白细胞介素-6与非抗白细胞介素-6生物改善病情抗风湿药物的使用模式：一项利用电子健康记录的真实世界研究
Rheumatol Adv Pract. 2024 Dec 14;9(1):rkae140. doi: 10.1093/rap/rkae140. eCollection 2025.
8
Tofacitinib Safety and Effectiveness in Canadian Patients with Rheumatoid Arthritis by Cardiovascular Risk Enrichment: Subanalysis of the CANTORAL Study.通过心血管风险富集评估托法替布在加拿大类风湿性关节炎患者中的安全性和有效性：CANTORAL研究的亚组分析。
Rheumatol Ther. 2024 Dec;11(6):1629-1648. doi: 10.1007/s40744-024-00719-5. Epub 2024 Nov 1.
9
Application of disease activity index in rheumatoid arthritis management in Korea.疾病活动指数在韩国类风湿关节炎管理中的应用。
J Rheum Dis. 2024 Oct 1;31(4):193-199. doi: 10.4078/jrd.2024.0077. Epub 2024 Aug 2.
10
Tuberculosis screening for patients on biologic Medications: A Single-Center experience and Society guideline Review, Monroe County, New York, 2018-2021.接受生物制剂治疗患者的结核病筛查：单中心经验及学会指南综述，纽约门罗县，2018 - 2021年
J Clin Tuberc Other Mycobact Dis. 2024 Jun 22;36:100460. doi: 10.1016/j.jctube.2024.100460. eCollection 2024 Aug.
本文引用的文献
1
Certolizumab pegol (CDP870) for rheumatoid arthritis in adults.聚乙二醇化赛妥珠单抗（CDP870）用于成人类风湿关节炎的治疗。
Cochrane Database Syst Rev. 2011 Feb 16(2):CD007649. doi: 10.1002/14651858.CD007649.pub2.
2
American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials.美国风湿病学会/欧洲抗风湿病联盟关于类风湿关节炎临床试验缓解的临时定义
Arthritis Rheum. 2011 Mar;63(3):573-86. doi: 10.1002/art.30129.
3
2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative.2010年类风湿关节炎分类标准：美国风湿病学会/欧洲抗风湿病联盟合作项目
Arthritis Rheum. 2010 Sep;62(9):2569-81. doi: 10.1002/art.27584.
4
Tocilizumab for rheumatoid arthritis.托珠单抗用于治疗类风湿关节炎。
Cochrane Database Syst Rev. 2010 Jul 7(7):CD008331. doi: 10.1002/14651858.CD008331.pub2.
5
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs.EULAR 推荐的使用合成和生物疾病修饰抗风湿药物治疗类风湿关节炎的建议。
Ann Rheum Dis. 2010 Jun;69(6):964-75. doi: 10.1136/ard.2009.126532. Epub 2010 May 5.
6
Golimumab for rheumatoid arthritis.戈利木单抗治疗类风湿关节炎。
Cochrane Database Syst Rev. 2010 Jan 20;2010(1):CD008341. doi: 10.1002/14651858.CD008341.
7
Biologics for rheumatoid arthritis: an overview of Cochrane reviews.类风湿关节炎的生物制剂：Cochrane系统评价概述
Cochrane Database Syst Rev. 2009 Oct 7;2009(4):CD007848. doi: 10.1002/14651858.CD007848.pub2.
8
Clinical and radiological efficacy of initial vs delayed treatment with infliximab plus methotrexate in patients with early rheumatoid arthritis.英夫利昔单抗联合甲氨蝶呤早期治疗与延迟治疗对早期类风湿关节炎患者的临床及影像学疗效
Ann Rheum Dis. 2009 Jul;68(7):1153-8. doi: 10.1136/ard.2008.093294. Epub 2008 Oct 17.
9
Effect of the early use of the anti-tumor necrosis factor adalimumab on the prevention of job loss in patients with early rheumatoid arthritis.早期使用抗肿瘤坏死因子阿达木单抗对预防早期类风湿关节炎患者工作能力丧失的影响。
Arthritis Rheum. 2008 Oct 15;59(10):1467-74. doi: 10.1002/art.24106.
10
Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial.甲氨蝶呤单药疗法与甲氨蝶呤和依那西普联合疗法治疗活动期、早期、中重度类风湿关节炎的比较（COMET）：一项随机、双盲、平行治疗试验
Lancet. 2008 Aug 2;372(9636):375-82. doi: 10.1016/S0140-6736(08)61000-4. Epub 2008 Jul 16.
Zotero 插件